Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 10/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.37 |
| ▸ | RORA | P35398 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 4/20 | 0.34 |
| ▸ | MLYCD | O95822 | 3/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | RORB | Q92753 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880561 | 0.80 | NR1H2 (0.42) | NR1H3NR1H2MLYCD | |
| SCHEMBL5595294 | 0.75 | NR1H2 (0.38) | NR1H3NR1H2SMN1; SMN2RORCMLYCD | |
| SCHEMBL4419153 | 0.74 | MLYCD (0.41) | NR1H3NR1H2SMN1; SMN2MLYCD | |
| SCHEMBL5595300 | 0.74 | MLYCD (0.41) | NR1H3NR1H2SMN1; SMN2MLYCD | |
| SCHEMBL4884879 | 0.73 | NR1H2 (0.46) | NR1H3NR1H2MLYCD | |
| SCHEMBL17803376 | 0.68 | RAB9A (0.48) | — | |
| SCHEMBL9145018 | 0.67 | RAB9A (0.48) | — | |
| SCHEMBL7248333 | 0.67 | GFER (0.46) | — | |
| SCHEMBL20853413 | 0.66 | RAB9A (0.48) | — | |
| SCHEMBL4883425 | 0.65 | MLYCD (0.44) | NR1H3NR1H2RORCMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4267920-B2 | — | — | 2009-05-27 | — | — | JP | claimed |
| US-7279477-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-09 | — | — | US | claimed |
| JP-2004523542-A | — | — | 2004-08-05 | — | — | JP | claimed |
| US-20040063671-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1377290-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-07 | — | — | EP | claimed |
| WO-2002064136-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063671-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | MLYCD, ACACA, ME1 | NR1H3 1471/4885NR1H2 1305/4885RORA 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.